目的 探讨肝苏胶囊联合黄芩苷胶囊治疗慢性乙型病毒性肝炎的临床疗效。方法 选取2013年6月-2016年1月鄂东医疗集团市中医医院诊治的慢性乙型病毒性肝炎患者88例，随机分为对照组和治疗组，每组各44例。对照组餐后30 min口服黄芩苷胶囊，0.5 g/次，3次/d。治疗组在对照组基础上餐后30 min口服肝苏胶囊，1.2 g/次，3次/d。两组患者均治疗6个月。观察两组的临床疗效，比较两组的丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、总胆红素（TBIL）、乙肝病毒的脱氧核糖核酸（HBV-DNA）、透明质酸、III型前胶原、IV型胶原和层粘连蛋白的情况。结果 治疗后，对照组和治疗组的总有效率分别为73.64%、86.36%，两组比较差异有统计学意义（P<0.05）。治疗后，两组ALT、AST、TBIL和HBV-DNA水平均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的下降程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组透明质酸、III型前胶原、IV型胶原和层粘连蛋白均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的下降程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 肝苏胶囊联合黄芩苷胶囊具有较好的临床疗效，能降低患者的ALT、AST、TBiL和HBV-DNA水平，减轻肝脏纤维化的程度，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Sugan Capsules combined with Baicalin Capsules in treatment of chronic hepatitis B. Methods Patients (88 cases) with chronic hepatitis B in Edong Healthcare City Hospital of Traditional Chinese Medicine from June 2013 to January 2016 were randomly divided into control and treatment groups, and each group had 44 cases. Patients in the control group were po administered with Baicalin Capsules after meals 30 min, 0.5 g/time, three times daily. Patients in the treatment group were po administered with Sugan Capsules on the basis of the control group after meals 30 min, 1.2 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and ALT, AST, TBIL, HBV-DNA, hyaluronic acid, type III procollagen, type IV collagen, and laminin in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.64% and 86.36%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of ALT, AST, TBIL, and HBV-DNA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, hyaluronic acid, type III procollagen, type IV collagen, and laminin in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Sugan Capsules combined with Baicalin Capsules has clinical curative effect in treatment of chronic hepatitis B, can decrease the levels of ALT, AST, TBIL, and HBV-DNA, and reduce the degree of liver fibrosis, which has a certain clinical application value.